The Food and Drug Administration’s recent approval of new Alzheimer’s drugs sparked a flicker of hope for the millions affected by this devastating disease. But this progress casts a puzzling shadow.
The drugs come at a high cost for relatively limited benefits, offering only a brief respite in the pace of cognitive decline. This reality raises a question: Are we fixated on such marginally effective treatments at the expense of more promising preventive measures?
Let's start with the truth!
Support the Broken Science Initiative.
Subscribe today →
recent posts
How “Logic” Can Lead One Astray. Webinar with Richard Johnson, MD.
Owners of Rose City MetFix share what they’re doing differently inside their MetFix Affiliate.
A scalable, lifestyle-first blueprint for PA training to improve readiness to prescribe movement and nutrition.
